bryan johnson ghk cu How one entrepreneur is tackling humanity's most pressing problems Bryan Johnson - 2019 -

This mini review summarizes neurotrophin biology relevant to bone sarcoma, delineates mechanisms by which these pathways reprogram immune and stromal compartments, and evaluates therapeutic strategies ranging from ligand/receptor blockade to clinically available TRK inhibitors, with the objective of defining tractable approaches to restore immune competence in this disease

GI events were the most common adverse effects, vast majority mild to moderate

What the research firmly supports: BPC-157's gut healing, vascular, and neuroprotective mechanisms (strong preclinical evidence) Thymosin Alpha-1's immune modulating and T-cell restorative effects (strong preclinical + clinical evidence in viral disease) TB-500's cardiovascular repair and angiogenic properties (strong preclinical, early human data) What the research does not yet confirm: Randomised controlled trial data specifically in long COVID populations Optimal dosing, sequencing, and duration specifically for PASC Long-term safety data for extended post-viral use This doesn't mean these peptides don't work for long COVID

The leading cause overall, especially among young children and older adults

GHRP-2 is a reasonable middle ground: stronger GH release than ipamorelin, moderate side effects